SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.

SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures.

Join us in shaping the future of medicine, where discovery meets dedication.

SPIMA Therapeutics

Org chart

Teams

Offices